IN8bio, Inc. (INAB)
NASDAQ: INAB · Real-Time Price · USD
0.1600
-0.0030 (-1.84%)
At close: May 13, 2025, 4:00 PM
0.1600
0.00 (0.00%)
Pre-market: May 14, 2025, 6:10 AM EDT
IN8bio Employees
IN8bio had 18 employees as of December 31, 2024. The number of employees decreased by 13 or -41.94% compared to the previous year.
Employees
18
Change (1Y)
-13
Growth (1Y)
-41.94%
Revenue / Employee
n/a
Profits / Employee
-$1,523,611
Market Cap
13.00M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 18 | -13 | -41.94% |
| Dec 31, 2023 | 31 | 5 | 19.23% |
| Dec 31, 2022 | 26 | 7 | 36.84% |
| Dec 31, 2021 | 19 | 5 | 35.71% |
| Dec 31, 2020 | 14 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
INAB News
- 1 day ago - IN8bio Presents Data at ISCT 2025 Demonstrating Proprietary γδ T cell Manufacturing Generates Consistent and Robust Clinical Products - GlobeNewsWire
- 6 days ago - IN8bio Reports First Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewsWire
- 14 days ago - IN8bio to Present Clinical and Preclinical Data from Gamma-Delta T Cell Platform at Upcoming Scientific Conferences - GlobeNewsWire
- 15 days ago - IN8bio Unveils Promising New Data from Next Generation Gamma-Delta T Cell Engager (TCE) Platform at AACR 2025 - GlobeNewsWire
- 6 weeks ago - IN8bio to Present New Preclinical Data on Novel Gamma-Delta (γδ) T cell Engager Platform for Cancer Immunotherapy at AACR Annual Meeting 2025 - GlobeNewsWire
- 2 months ago - IN8bio to Participate at the 11th Annual Immuno-Oncology 360° Conference 2025 - GlobeNewsWire
- 2 months ago - IN8bio Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 2 months ago - IN8bio Announces Advanced Gamma-Delta (γδ) T cell Engager (TCE) Platform for Oncology and Autoimmune Diseases - GlobeNewsWire